165 related articles for article (PubMed ID: 28730672)
1. Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET).
De Gennaro Colonna V; Pavanello C; Rusconi F; Sartore-Bianchi A; Siena S; Castelnuovo S; Sirtori CR; Mombelli G
J Clin Pharm Ther; 2018 Feb; 43(1):114-116. PubMed ID: 28730672
[TBL] [Abstract][Full Text] [Related]
2. Everolimus causing severe hypertriglyceridemia and acute pancreatitis.
Subramaniam S; Zell JA; Kunz PL
J Natl Compr Canc Netw; 2013 Jan; 11(1):5-9. PubMed ID: 23307976
[TBL] [Abstract][Full Text] [Related]
3. [Lipid lowering treatment of severe hypertriglyceridemia with acute pancreatitis caused by everolimus in a patient with a neuroendocrine tumor].
De Carlos Artajo J; Castro Unanua N; Muruzábal Huarte E; Vera García R; Irigaray Echarri A; Zubiría Gortázar J; Anda Apiñániz E
An Sist Sanit Navar; 2020 Apr; 43(1):103-106. PubMed ID: 32242549
[TBL] [Abstract][Full Text] [Related]
4. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
6. Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors.
Pavel ME; Chen D; He W; Cushman S; Voi M; de Vries EGE; Baudin E; Yao JC
Pancreas; 2017 Jul; 46(6):751-757. PubMed ID: 28609362
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic Control of Neuroendocrine Tumours with Everolimus.
Bainbridge HE; Larbi E; Middleton G
Horm Cancer; 2015 Dec; 6(5-6):254-9. PubMed ID: 26245686
[TBL] [Abstract][Full Text] [Related]
8. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms.
Lee L; Ito T; Igarashi H; Ueda K; Fujiyama T; Kawabe K; Ogawa Y
J Hepatobiliary Pancreat Sci; 2017 Feb; 24(2):95-102. PubMed ID: 27926987
[TBL] [Abstract][Full Text] [Related]
9. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns and Burden of Illness in Patients Initiating Targeted Therapy or Chemotherapy for Pancreatic Neuroendocrine Tumors.
Broder MS; Chang E; Reddy SR; Neary MP
Pancreas; 2017 Aug; 46(7):891-897. PubMed ID: 28697129
[TBL] [Abstract][Full Text] [Related]
11. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
12. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
13. Everolimus in Pancreatic Neuroendocrine Carcinomas G3.
Panzuto F; Rinzivillo M; Spada F; Antonuzzo L; Ibrahim T; Campana D; Fazio N; Delle Fave G
Pancreas; 2017 Mar; 46(3):302-305. PubMed ID: 28099254
[TBL] [Abstract][Full Text] [Related]
14. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs).
Vernieri C; Pusceddu S; Fucà G; Indelicato P; Centonze G; Castagnoli L; Ferrari E; Ajazi A; Pupa S; Casola S; Foiani M; Mazzaferro V; Pruneri G; Milione M; de Braud F
Int J Cancer; 2019 Apr; 144(7):1704-1712. PubMed ID: 30520016
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow edema associated with everolimus.
McDevitt RL; Quinlan C; Hersberger K; Sahai V
Am J Health Syst Pharm; 2018 Jan; 75(1):e23-e27. PubMed ID: 29273609
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
[TBL] [Abstract][Full Text] [Related]
17. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study.
Yao JC; Pavel M; Lombard-Bohas C; Van Cutsem E; Voi M; Brandt U; He W; Chen D; Capdevila J; de Vries EGE; Tomassetti P; Hobday T; Pommier R; Öberg K
J Clin Oncol; 2016 Nov; 34(32):3906-3913. PubMed ID: 27621394
[TBL] [Abstract][Full Text] [Related]
18. A case of erythema multiforme-like rash induced by everolimus in a patient with a pancreatic neuroendocrine tumor.
Mizuno Y; Ito T; Ueda K; Tashiro A; Kubota Y; Yamashita A; Miura M; Hayama H; Oya M; Tsuneyoshi M
Clin J Gastroenterol; 2022 Dec; 15(6):1193-1197. PubMed ID: 36264476
[TBL] [Abstract][Full Text] [Related]
19. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T
Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Long-Term Safety of Everolimus in Pancreatic Neuroendocrine Tumor Associated with Multiple Endocrine Neoplasia Type I: Case Report.
Maia MC; Muniz Lourenço D; Riechelmann R
Oncol Res Treat; 2016; 39(10):643-645. PubMed ID: 27710978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
